|Day's Range||14.80 - 15.05|
|52 Week Range||12.65 - 17.10|
|PE Ratio (TTM)||-9.14|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Acer Therapeutics, a three-year-old Cambridge biotech developing drugs for ultra-rare diseases, said Monday that it will go public through a reverse merger with a small Texas company. Acer said it would merge with Opexa Therapeutics (OPXA), which laid off all but two of its 20 employees after its lead drug for multiple sclerosis flunked a mid-stage trial in October. In connection with the deal, Acer said it would receive a $15.7 million round of financing led by TVM Capital, a life sciences venture firm based in Germany.
After consummation Opexa's name will be changed to Acer Therapeutics Inc.
Microsoft and its partners unveiled new laptops aimed at challenging Google at the low end of the education market and Apple at higher prices.